Search
Zevra Therapeutics Inc
ZVRAAdd to Watchlist
9.510USD
-0.130-1.35%
Close 07-31 16:00（ET）Quotes delayed by 15 min
562.18MMarket Cap
4.51P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Zevra Therapeutics Inc is 8.67, ranking 12 out of 155 in the Pharmaceuticals industry. The average price target is 24.00, with a high of 26.00 and a low of 18.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
25.000
Target Price
+155.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Zevra Therapeutics Inc
ZVRA
9
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Zevra Therapeutics Inc's expected revenue for the next quarter?
Zevra Therapeutics Inc's expected revenue is 33.88M.
What is Zevra Therapeutics Inc's price target?
Analysts forecast that Zevra Therapeutics Inc's price target is USD 24.00, with the highest forecast at USD 26.00 and the lowest forecast at USD 18.00.
How have Zevra Therapeutics IncZVRA's recent earnings per share performed?
The market expectation was USD 0.65, while Zevra Therapeutics IncZVRA's earnings per share (EPS) for the previous quarter was USD 0.21. EPS for the next quarter is expected at USD 0.11.
What is the analyst rating for Zevra Therapeutics Inc?
Based on the ratings of Zevra Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.